DocWire News Editors

DocwireNews

In the era of precision medicine, it is becoming more common to differentiate patients with severe asthma based on their pathophysiology to identify which new biologic treatment is most appropriate. Asthma type is classified based on the inflammatory molecular mechanism and most are familiar with the Type 2 inflammatory pathway versus the non-Type 2 pathway&mdash;also, commonly referred to as eosinophilic versus non-eosinophilic. There is an unmet need for treatments for non-Type 2 asthma. But there are several different biological treatments that target the Type 2 pathway and physicians can struggle in deciding which treatment would be best for which patient. Currently, the four biological therapies with specific targets in the Type 2 pathway, which are approved by the FDA for use in severe asthma are:<ul>
<li>Omalizumab (targets IgE);</li>
<li>Mepolizumab and reslizumab (targets IL-5); and</li>
<li>Dupilumab (targets IL-4/IL-13; recently approved in October 2018, so most guidelines are not yet updated to reflect this approval).</li>
</ul>One informative treatment approach is to understand the phenotype through measuring and grouping the biomarkers that contribute. Biomarkers indicate the extent of disease present in an individual. For Type 2 asthma there are six proposed biomarkers: blood eosinophils, FeNO, Total IgE, Specific IgE, Periostin, and DPPT4. Evidence from several studies supports overlapping biomarkers that help inform the particular phenotype of asthma that the patient has, but there are still not enough data to completely understand the ratios/profile of each biomarker to distinguish the molecular pathway to be targeted.In order to begin to tease apart which level of which biomarker represents a certain population of patients with severe asthma, Stephen Peters, MD, PhD, the Thomas H. Davis Chair in Pulmonary Medicine at Wake Forest School of Medicine, and colleagues conducted a the Precision Medicine in Severe Asthma (PrecISE) trial, a multi-center phase 2 trial with an adaptive design. The primary objectives of the trial are:<ul>
<li>identify novel therapies that work in biomarker-defined subgroups or severe asthmatic patients, and</li>
<li>optimize the subgroups targeted for treatment by refining the biomarkers and subgroup definitions.</li>
</ul>The premise of the trial is that each of the biological treatments has a role in severe asthma therapy. In order to determine the patients in whom each treatment is most efficacious, an understanding of the asthma phenotype/biomarker subgroup is required. Although a head-to-head trial comparing the efficacy of the biological treatments has been requested among asthma researchers, Dr. Peters urged his colleagues to reconsider , as &ldquo;that type of trial would be dependent on the patient population that is enrolled in the study,&rdquo; he said, suggesting instead to &ldquo;focus on identifying patient characteristics that give an individual patient the best chance to respond to the best biologic for him/her.&rdquo;As severe asthma treatment in practice is based on the type of asthma the patient has, treatments tend to be personalized. &nbsp;Physicians are already checking on how inflammation is mediated in patients, but this approach may not be enough. &ldquo;N of 1&rdquo; clinical trials could be a strategy to further individualize asthma treatment through genome sequencing and collecting individual data points in a database. The goal is to ultimately create a network of information about different groups of patients that follow similar responses to the same treatment. This builds upon defining the subgroups of asthma patients defined by specific molecular biomarkers by using phenotypes and N of 1 trials to further personalize asthma treatment.&ldquo;We are moving towards more personalized and precise medicine,&rdquo; Peters concluded.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Asthma Phenotypes: Evolution from Clinical to Molecular Approaches

ACAAI 2018

In the era of precision medicine, it is becoming more common to differentiate patients with severe asthma based on their pathophysiology to identify which new biologic ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe